Professor Liu Guobin used traditional Chinese medicine to cure a case of primary erythema limb pain

Primary erythema limb pain is a very rare disease,and its pathogenesis is not clear.Usually,the pain symptoms of patients exist for a long time,which seriously affect the daily life of patients and increase the economic burden of patients.Professor Liu Guobin,who has been engaged in the diagnosis and treatment of peripheral vascular diseases for nearly 30 years,believes that heat-toxin and blood stasis collaterals are closely related to the disease,and emphasizes the principle of heat-toxin and evil qi causing the disease.It is emphasized that clearing heat and detoxification,promoting blood circulation and dispersing blood stasis are the main treatment principles.This paper selects a typical case to describe Professor Liu's clinical experience in the treatment of primary erythema limb pain by oral and external use of traditional Chinese medicine,so as to provide an effective method of traditional Chinese medicine for the treatment of primary erythema limb pain.

Summary of Zhang Hongxing's Experience in Treating Refractory Angina Pectoris with Traditional Chinese Medicine

As a famous traditional Chinese medicine(TCM)expert in Shandong province and a famous veteran TCM expert in Dezhou city,Zhang Hongxing has been engaged in cardiovascular clinical work for more than 30 years.He has unique experience in the treatment of refractory angina pectoris.This paper comprehensively explains from the aspects of etiology and pathogenesis.His treatment is mostly based on syndrome differentiation,combined with the basic pharmacology of modem Chinese medicine to formulate prescriptions and drugs,and at the same time values the use of insect drugs.We hereby attach the clinical records,hoping to provide reference for clinical workers,which is conducive to the inheritance and development of famous Chinese medical academic experience.

Clinical research report on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions(2022)

Objective:The paper is to comprehensively summarize and analyze the basic situation and methodological quality of clinical randomized controlled trials(RCTs)of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions published in 2022,to provide evidence and reasonable suggestions for the advancement of clinical research and the formulation of policies and guidelines.Methods:The Evidence Database System of clinical evidence-based evaluation of traditional Chinese medicine was searched,and data from China National Knowledge Infrastructure(CNKI),PubMed,and other databases were supplemented.The search duration was from January 1,2022,to December 31,2022.RCTs of traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were included as the source of clinical evidence,and published information,sample size,intervention,control measures,treatment course,methodological quality,and key link report were analyzed and evaluated.Results:A total of 1,464 RCTs of traditional Chinese patent medicines were included,which comprised 667 types of traditional Chinese patent medicines;“traditional Chinese patent medicines+Western medicine vs.Western medicine”was the most widely used intervention and control setting,involving 417 RCTs(28.48%).A total of 245 RCTs of traditional Chinese classic famous prescriptions were included,comprising 55 types of traditional Chinese classic famous prescriptions.“Decoction+conventional treatment vs.conventional treatment”was the most widely used intervention and control setting,with 87 RCTs(35.51%).Published RCTs on traditional Chinese patent medicines and traditional Chinese classic famous prescriptions were limited by the study design and implementation.Most“allocation concealment”and“blinding of patients and personnel”were rated as medium to high risk.There are insufficient reports on key research links such as experimental registration and ethical approval.Conclusions:The number of RCTs on traditional Chinese patent medicines has decreased in 2022,but there has been a slight improvement in the research quality and impact.There are relatively few studies on traditional Chinese classic famous prescriptions.Measures must be taken to improve clinical trial design,implementation,and reporting.Methodological experts should be invited to provide professional technical guidance on the trial design.In the research implementation process,attention should be paid to quality control,particularly the standardization of the randomized execution.

王柏枝“肝肾同治”思想在阴茎勃起功能障碍诊治中的应用

阴茎勃起功能障碍(ED)发病机制复杂,不但是男性普遍存在的性健康问题,而且还是一个社会问题。王柏枝认为ED病情有急缓之分,病位有肝肾之别。以肾为本、肝为标,并有湿、痰、瘀夹杂其中,或有阴虚,或有内热。ED急发常责之于肝,有肝气郁结,肝经湿热,肝肾亏虚,常用疏肝理气之逍遥散、清肝利湿之龙胆泻肝汤、滋阴养肝之滋水清肝饮等。缓发养肾,自创起痿丸温肾阳、暖命门、补肾精、强宗筋、活血脉、健脾养肝。

杭州市基层医疗卫生机构慢性颈肩痛患者社区中医师信任度调查

目的:了解杭州市基层医疗卫生机构慢性颈肩痛患者对社区中医师的信任度及影响因素。方法:采用自制基线调查表、维克森林医师信任度量表中文版、自制满意度量表和长海痛尺表对杭州市3家社区中的244名慢性颈肩痛患者开展信任度调查。用t检验和方差分析比较差异,采用多元线性逐步回归分析信任度得分的影响因素。结果:社区中医师平均信任度得分为(39.59±3.23)分,仁爱维度、技术能力维度得分分别为(19.32±1.96)分、(20.27±1.61分)。多因素分析结果显示,随访是否有效、文化程度、自我健康状况评分、满意度评价、中医体质以及长海痛尺评分影响对医生的信任度。结论:杭州市基层卫生机构慢性颈肩痛患者对社区中医师总体信任度处于较高水平。社区中医师要加强医学人文关怀,积极引导患者参与到诊疗过程中,重视和提高慢性病患者随访时的技术水平和关怀程度。基层医疗卫生机构应当进一步完善诊后随访流程,加大慢性病中医健康管理优势的宣传,树立分级诊疗意识,完善诊疗环境建设,形成医患信任关系的良好循环。

安效先教授“平、调、截”三法干预小儿过敏进程经验浅谈

过敏性疾病的发生有一定的顺序,表现为特应性皮炎(Atopic dermatitis,AD)、食物过敏(Food allergy,FA)、过敏性哮喘(Allergic asthma,AA)和变应性鼻炎(Allergic rhinitis,AR)的顺序发展,被称为“过敏进程”。安效先教授提出了小儿少阳之体与过敏进程的联系,认为过敏进程与小儿不同时期的脏腑阴阳失衡状况有一定的关系。文中总结了安效先教授“平衡阴阳、调和营卫以及扭转截断”三法干预过敏进程的经验,并对“平、调、截”三法在湿疹、特应性皮炎、食物过敏、支气管哮喘以及过敏性咳嗽等不同过敏进程的疾病治疗中的应用加以具体介绍,希望能够为中医药干预过敏进程提供更多的理论基础支撑。

王珂名老中医基于“天癸理论”论治痤疮经验

痤疮是一种较常见且易反复发作的皮肤病,王珂教授对治疗痤疮有其独到的认识和治疗经验,提出对痤疮病机认识应从“天癸理论”出发,结合后天脾胃易损,认为天癸失衡,肾中阴阳失调是痤疮产生的内在因素;后天脾胃易损、冲任二脉失司、脾虚生湿、湿郁化热、阻滞局部导致发病;病后气机不畅,痰瘀阻络,瘢痕色素形成。在治疗上以补天癸,调阴阳治其根,清热利湿、调和局部气血除其标,提倡固本兼除标,临床中常用滋肾、清热、凉血、行气之法治之,常收良效。

谈平教授治疗类风湿关节炎临床经验

谈平教授认为类风湿关节炎的基本病机是本虚标实,根据多年临床经验,提出治疗类风湿关节炎早期以温通散寒、兼化瘀为主,后期以温经通络、滋补肝肾、兼化瘀为主,温经、化瘀贯穿整个治疗过程。谈平教授在治疗类风湿关节炎上重视辨病辨证相结合,中药功效与现代药理相结合,虫类药与藤类药相配,根据病位选用引药。本文总结谈平教授治疗类风湿关节炎的临床经验,以期为中医药治疗类风湿关节炎提供思路。

名老中医手法治疗神经根型颈椎病经验述要

神经根型颈椎病(CSR)属中医学项痹、颈项痛、项肩痛等范畴,当代名老中医手法治疗该病经验丰富、疗效显著。本文通过梳理国家级、省级、市级名老中医手法治疗CSR相关文献,总结名老中医对CSR的病因病机认识,分析其以手法治疗CSR时遵循的原则,提炼其特色手法操作,为传承发展名老中医手法治疗CSR学术思想奠定基础。参考文献34篇。

林兰教授从心论治糖尿病经验

由于社会老龄化的发展、人们生活水平的提高、工作压力的增加等原因,糖尿病发病率逐年上升,防治糖尿病成为临床治疗的重点与难点。林兰教授基于心的生理特性,结合其长期临床经验,从心阐释糖尿病病机,认为本病因心气郁结而起,心火不降化为火毒而致糖毒性,凸显病情进展,心阳亏虚致痰瘀互结而并发症丛生。治疗上另辟蹊径,以心为切入点,遵循“调神”“调气”“调形”,临证灵活运用清润安神、滋精养神、益气养心、通降心气、活血化痰等法,为中医药治疗糖尿病提供了新思路、新方法。

基于数据挖掘名老中医食管癌医案探讨虫类药物作用机制的研究进展

目的:通过数据挖掘分析名老中医诊治食管癌医案,发掘其中虫类药物的运用规律并对其作用机制进行探讨。方法:①以国家中医药管理局公布的第一批至第三批国医大师和第一批至第六批全国老中医药专家学术经验继承工作指导老师名单为依据,在河南中医药大学图书馆馆藏书目检索系统输入名老中医姓名,检索其著作、经验集,从中寻找其诊治食管癌的医案。②以名老中医姓名、“食管癌”“中医”“医案”“临床经验”为检索词,分别检索中国知网、万方数据知识服务平台、维普中文科技期刊数据库自建库至今公开发表的食管癌诊治医案,提取医案详细信息,包括诊断、处方药物、虫类药物、证型,运用中医传承辅助平台对处方药物的四气五味、归经、用药频次、虫类药物频次、证型分布进行分析。结果:共纳入331个处方、344味药物,使用频次居前10位的分别为茯苓、黄芪、陈皮、白术、甘草、威灵仙、麦冬、白花蛇舌草、党参、砂仁。证候频次居前10位的依次为痰瘀互结、气阴两虚、痰气交阻、瘀毒互结、胃气上逆证、脾气虚证、脾肾两虚证、脾胃虚弱、气滞血瘀、痰湿内停。其中所涉虫类药物频次居前10位的分别为:壁虎、蜈蚣、全蝎、僵蚕、蜂房、穿山甲、土鳖虫、蟾皮、水蛭、乌梢蛇。

香港地区中医执业资格考试之现况与改革建议

目前国家把中医药传承发展需要的中医临床合格人才作为中医执业资格考试的目的。通过香港地区、内地(大陆)与台湾地区三地执业资格考试现况的比较,从中医发展现况、国家中医人才需求及本地中医业界意见等入手探讨香港地区的中医执业资格考试制度。结论是因目前所需的中医人才在中医思维、经典与临床实践能力都有较高的要求,故执业资格考试亟需在目的、内容、方式、参加资格与课程要求等方面做相应改革,并结合有系统的中医人才培训计划及资历架构以提升中医专业素质,另建议设立“香港中医专业学院”以进行执业资格考试的相关改革事宜。

黑龙江省名中医秦克力教授治疗疼痛类疾病的用药规律分析

目的通过数据挖掘的方法探究黑龙江省名中医秦克力教授治疗疼痛类疾病处方的用药规律,从而为中医临床治疗疼痛类疾病提供一些客观的理论依据。方法选取黑龙江省名中医秦克力教授治疗疼痛类疾病病历中符合纳入采样标准的方剂中的中药,采样建立数据库,并分别应用数据处理软件对数据进行描述性、关联规则性、复杂网络链接关系性、系统聚类性分析,以研究黑龙江省名中医秦克力教授治疗疼痛类疾病的处方用药规律。结果本次研究共纳入了102味药物,98首方剂。其中通过对元胡、柴胡、白芍、鸡血藤、川芎、穿山龙、威灵仙等高频使用的药物,分析得到关联规则48条,分析复杂网络连接关系得到强链接3组、中等链接15组,分析系统聚类得到常用方组6组。结论黑龙江省名中医秦克力教授处方治疗疼痛类疾病辨证论治、表里同施、邪正兼顾。

陆拯“健脾清肠解毒”治疗结肠癌经验举隅

[目的]总结国医名师陆拯教授“健脾清肠解毒”治疗结肠癌的临证经验。[方法]通过门诊跟诊学习,病案收集整理,查找结肠癌相关文献及中医典籍,研习陆拯教授所著之《毒证论》,结合教授的临证释义,探讨结肠癌的病因病机,阐释结肠癌的治疗方法为“毒证四层总纲”指导下的“健脾清肠解毒”,归纳其临证辨证施治要点及组方用药规律,并附验案加以佐证。[结果]陆拯教授认为结肠癌基本病机是脾胃元气受损、癌毒蓄积于肠,并进一步指出脾胃元气受损是结肠癌发生、发展的前提,癌毒蓄积于肠是结肠癌发生、复发和转移的关键,临证治疗当着眼于恢复脾胃元气,清除肠中湿、热、痰、瘀等内生邪气以及残余癌毒,条畅肠腑气机,即以“健脾清肠解毒”为指导思想,根据患者术后具体症状,归纳为湿热毒蕴、痰瘀毒阻、瘀血毒壅、阳虚寒毒、阴虚热毒五种证型,基于扶正拔毒并举的理念,分别以清热解毒、化痰祛瘀、化瘀逐毒、温阳拔毒、滋阴败毒论治,从而祛除术后余毒,杜绝新生癌毒。所举医案应用“健脾清肠解毒”法治疗后症状改善,生活质量提高,随访无肿瘤复发转移。[结论]陆拯教授“健脾清肠解毒”治疗结肠癌的临证经验,展示了陆拯毒证理论在肿瘤治疗中的应用,为结肠癌的中医辨治提供了借鉴。

中医执业医师资格第一阶段实践技能考试研究现状及策略

文章介绍我国中医执业医师第一阶段实践技能考试内容及研究现状,总结宁夏医科大学学生在实践技能考试中存在的问题;以五年制中医相关专业学生为研究对象,通过建立实训室、促进教学改革、实施教师责任制等措施,提高第一阶段实践技能成绩。采取一系列措施后,学校中医专业技能考核通过率较之前有所提高,收获了学生、实习单位、用人单位、教师等多方的良好反馈,但仍要理性看待技能考试通过率,继续完善改革措施,进一步提高学生的临床实践能力。

20世纪60年代苏州吴县中医讲习班考究

在始于1956年的全国中医带徒弟运动蓬勃发展的历史背景下,苏州吴县中医讲习班于1963年应运而生。中医讲习班现存相关史料少见且分布零散,通过多方搜集整理及调研,从开班背景、招生对象、收费情况、教学安排、师徒概况及结业情况等方面,对20世纪60年代吴县中医讲习班具体状况进行梳理,部分再现了讲习班历史原貌,对吴门医派研究及当地中医的传承发展具有一定借鉴意义。

新医科背景下七个结合助推卓越中医师培养实践

新医科背景下,卓越中医师教育培养坚持传承与创新结合,以立德树人为引领,强化中医思维能力和实践技能培养。文章从理论与实践结合、专业知识与文化教育结合、师承教育与院校教育结合、中医药教育与民族医教育结合、形成性评价与终结性评价结合、线上教育与线下教育结合、创新教育与素质教育结合出发,探讨实践培养适应我国医疗卫生事业发展需要的卓越中医师培养体系。

杨廉方基于肝脾同调论治癌性呃逆的临证精粹

癌性呃逆为肿瘤患者经历的常见的病症之一,目前西医学对该病的致病因素和发生机制尚未明确,治疗上常选用甲氧氯普胺、巴氯芬等药物治疗,但在长期使用后易产生复发性和耐药性。杨廉方教授系重庆市名中医,并担任第五批全国老中医药专家学术经验传承工作的指导老师,擅长运用中医药治疗肿瘤、脾胃病等疾病。杨廉方教授认为脾阳不足、肝气犯胃为发生癌性呃逆的关键病因,其病机主要为肝脾失和。强调癌性呃逆日久易“痰”易“湿”易“瘀”,故当明确标本,辨明虚实,治疗当分清轻重缓急,并兼顾受扰之邪,为临床治疗癌性呃逆提供了新思路。附验案1例以佐证。

疏肝和胃汤治疗小儿急性肠系膜淋巴结炎经验探析——以凌湘力教授经典医案为例

凌湘力教授认为小儿急性肠系膜淋巴结炎导致的腹痛病在大肠筋膜,与肝脾密切相关,其基本病机为气机失调,脾胃肠腑气滞,不通则痛,基本治法以调肝理脾、调和气机、行气止痛为主,自拟疏肝和胃汤治疗小儿腹痛肝脾不和型,收效显著。疏肝和胃汤由柴胡、白芍、枳壳、香附、郁金、茵陈、金钱草、黄芩、炒谷芽、炒麦芽、延胡索、甘草十二味药组成。全方共奏疏肝和胃、清热利湿止痛之功,纠正肝胆脾胃气郁湿热等失衡失和之状态,适用于肝脾不和兼有湿热内蕴者。对经典医案进行了总结,以资校验。

Experience inheritance from famous specialists based on real- world clinical research paradigm of traditional Chinese medicine

The current modes of experience inheritance from famous specialists in traditional Chinese medicine （TCM） include master and disciple, literature review, clinical-epidemiology-based clinical research observation, and analysis and data mining via computer and database technologies. Each mode has its advantages and disadvantages. However, a scientific and instructive experience inheritance mode has not been developed. The advent of the big data era as well as the formation and practice accumulation of the TCM clinical research paradigm in the real world have provided new perspectives, techniques, and methods for inheriting experience from famous TCM specialists. Through continuous exploration and practice, the research group proposes the innovation research mode based on the real-world TCM clinical research paradigm, which involves the inheritance and innovation of the existing modes. This mode is formulated in line with its own development regularity of TCM and is expected to become the main mode of experience inheritance in the clinical field.